• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Anti-NMDA Receptor Encephalitis or New-Onset Psychosis?

Anti-NMDA Receptor Encephalitis or New-Onset Psychosis?

July 14, 2021
Alex Thompson, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Alex Thompson, MD. Dr. Thompson has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Xu X et al, Neurol Neuroimmunol Neuroinflamm 2019;7(1):e633

You may have heard of the book Brain on Fire: My Month of Madness by Susannah Cahalan (later made into a movie). Cahalan, a successful journalist, describes her brief psychotic episode that led to hospitalizations and mistaken psychiatric diagnoses. She was eventually diagnosed with anti-NMDA receptor encephalitis, in which the body produces antibodies to NMDA receptors, causing a variety of psychiatric and neurological symptoms. The diagnosis requires detecting the antibodies in the cerebrospinal fluid (CSF).

Anti-NMDA receptor encephalitis typically presents in younger women (many of whom have an ovarian teratoma), and early identification and treatment is key to prevent substantial morbidity or death. To halt ongoing brain injury, the standard of care is immunosuppression treatment in the form of steroids, plasmapheresis, intravenous immunoglobulin (IVIG), monoclonal antibodies (rituximab), and cyclophosphamide.

To help develop better treatment guidelines, Chinese investigators published a 12-month observational study of 220 patients with anti-NMDA receptor encephalitis. The goal was to better characterize the presentation, clinical course, and outcome of the disease. Long-term outcomes were measured using the modified Rankin Scale (mRS), a 6-point scale (0 = no disability, 5 = severe disability) used to assess disability outcomes in patients who have had strokes.

The findings affirm what we know about anti-NMDA receptor encephalitis: 65% of patients were female (of which 30% had teratomas), the median age was 21 years old, and only 36% had abnormal MRI findings on presentation. At initial presentation, 83% had psychosis, 81% had seizures, and 51% had abnormal EEG findings. While 100% had CSF antibodies to NMDA receptors, only 71% had serum antibodies, meaning blood work alone cannot rule out the disease.

The outcomes give us hope: While the median disability score at onset was 4 (moderately severe disability), at 12 months, 93% of the cohort had no more than a slight disability, with over 60% showing no symptoms. Overall, the median time from diagnosis to treatment was 2 weeks.

CHPR’s Take
While uncommon (the incidence is 1.5 per million people per year), anti-NMDA receptor encephalitis should be on our psychosis differential, especially for younger women with new-onset psychosis who have a history of a viral prodrome and subtle neurologic abnormalities. In such patients, you should have a low threshold for consulting neurology, and for ordering neuroimaging, EEG testing, and CSF analysis.
Hospital Psychiatry
KEYWORDS anti-nmda-receptor-encephalitis encephalitis female-issues-in-psychiatry nmda psychosis womens-issues-in-psychiatry
    Alex Thompson, MD.

    More from this author
    www.thecarlatreport.com
    Issue Date: July 14, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Metabolic Side Effects, CHPR, July/August/September 2021
    Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain
    Weight Gain and Metabolic Side Effects
    Sex-Based Treatment of Schizophrenia
    New Combination Treatment Mitigates Antipsychotic-Induced Weight Gain
    Anti-NMDA Receptor Encephalitis or New-Onset Psychosis?
    Psilocybin: The New Holy Grai­l for the Rapid Relief of Major ­Depression?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.